OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results
OPKO Health reported a net loss of $86.1 million or $0.11 per share for Q3 2022, compared to a net income of $28.7 million or $0.04 per diluted share in Q3 2021. Total revenues were $179.7 million, down from $385.8 million, largely attributed to a significant decrease in COVID-19 testing volume at BioReference Laboratories. Notably, the company’s operating loss reached $87.8 million, influenced by increased costs linked to acquisitions and product development. However, OPKO anticipates higher royalty payments related to Pfizer’s NGENLA as it gains additional pricing approvals.
- Expected increase in royalty payments from NGENLA as Pfizer expands into new markets.
- Cost reduction efforts at BioReference Laboratories have already saved over $100 million annually.
- Total revenues decreased by approximately 53% year-over-year.
- Operating loss widened significantly to $87.8 million in Q3 2022, compared to operating income in Q3 2021.
- Net loss included a non-cash expense of $30.6 million due to a decline in the fair value of Sema4 investment.
Conference call begins at 4:30 p.m. Eastern time today
MIAMI, Nov. 08, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2022.
Business highlights for the third quarter of 2022 and subsequent weeks include the following:
- Pfizer’s NGENLA® (somatrogon) launched in Japan, Germany and other global markets; Pfizer seeking pricing approvals in additional European countries and continuing to work with FDA to obtain approval in the U.S. NGENLA treats pediatric patients with decreased growth due to insufficient growth hormone and reduces the injection frequency from once daily to once weekly. NGENLA is the first once weekly product approved for the treatment of pediatric growth hormone deficiency in Japan, Canada, Australia, Taiwan, UAE and Brazil. Its European Union marketing authorization is valid in all EU Member States as well as Iceland, Norway and Liechtenstein. In Australia, NGENLA is now offered through the Pharmaceutical Benefits Scheme, Australia’s national drug subsidy program.
- ModeX Therapeutics, Inc. (ModeX) progresses proprietary immunotherapy pipeline. ModeX continues to advance its pipeline of antiviral and immune-oncology products utilizing its next generation multispecific antibodies. In addition, ModeX is pursuing potential licensing and collaboration arrangements with strategic partners for certain of its early stage pipeline candidates.
- Innovation and cost cutting efforts continue at BioReference Laboratories (BRL). BRL continues significant cost reduction and business rationalization efforts following the decline of COVID testing volume. These efforts have resulted in a reduction of more than
$100 million in annualized costs to date. Furthermore, BRL is exploring other revenue sources to work toward returning BRL to profitability.
Third Quarter Financial Results
- Pharmaceuticals: Revenue in the third quarter of 2022 decreased to
$32.4 million from$36.9 million in the third quarter of 2021, driven by foreign currency exchange and lower sales of RAYALDEE. During the third quarter of 2022, OPKO received gross profit share and royalty payments from Pfizer related to sales of NGENLA. We expect these payments to increase as Pfizer receives additional pricing approvals and launches the product in other geographies. Revenue from sales of RAYALDEE in the third quarter of 2022 was$6.9 million compared with$8.5 million in the prior-year period; however, we also began to receive royalty payments from sales of RAYALDEE by CSL Vifor in Germany and Switzerland during the third quarter of 2022. We expect these payments to increase as CSL Vifor launches RAYALDEE in additional territories throughout Europe. There were several significant events that positively impacted third quarter 2021 results, and should be considered when comparing those results to 2022. Revenue from the transfer of intellectual property was$4.5 million in the third quarter of 2022 compared with$8.8 million in the 2021 period. The third quarter of 2021 also included$4.9 million related to an exclusive license agreement with CAMP4 Therapeutics Corp. and$1.0 million due to the joint venture with LeaderMed Health Group Ltd. Total costs and expenses were$65.2 million in the third quarter of 2022 compared with$17.0 million in the prior-year period, which included a$31.5 million gain on the sale of OPKO’s fill-finish manufacturing facility in Ireland to Horizon Therapeutics. In addition, the increase in total costs and expenses in the third quarter of 2022 was primarily attributable to higher amortization expenses related to the reclassification of NGENLA’s in-process research and development upon its approval in Europe and Japan, higher employee expenses associated with the ModeX acquisition and higher research and development costs for somatrogon, partially offset by foreign currency exchange. The operating loss of$28.3 million in the third quarter of 2022 compared to operating income of$28.6 million in the third quarter of 2021 reflects these events. - Diagnostics: Revenue from services in the third quarter of 2022 was
$142.8 million compared with$340.1 million in the prior-year period, the decrease primarily due to lower COVID-19 testing volume. BRL processed approximately 0.2 million COVID-19 PCR tests in the third quarter of 2022 versus 2.2 million tests in the third quarter of 2021. Total costs and expenses were$192.3 million in the third quarter of 2022 compared with$320.5 million in the third quarter of 2021, resulting in an operating loss of$49.5 million compared with operating income of$19.7 million in the 2021 period. BRL continues to implement significant cost-reduction initiatives and scaled back digital health investments as it looks to return to profitability following the buildup and then decline of COVID-related testing. The third quarter of 2022 included$5.1 million in severance costs as the company reduced employee costs on an annualized basis by over$46 million . - Consolidated: Consolidated total revenues for the third quarter of 2022 were
$179.7 million compared with$385.8 million for the comparable period of 2021. Operating loss for the third quarter of 2022 was$87.8 million compared with operating income of$37.8 million for the 2021 quarter. Net loss for the third quarter of 2022 was$86.1 million , or$0.11 per share, compared with net income of$28.7 million , or$0.04 per diluted share, for the 2021 quarter. Net loss for the third quarter of 2022 included a non-cash expense of$30.6 million due to a decrease in the fair value of OPKO’s Sema4 investment, while the comparable quarter of 2021 included a$31.5 million gain on the sale of the facility in Ireland. - Cash and cash equivalents: Cash and cash equivalents were
$180.8 million as of September 30, 2022.
Conference Call and Webcast Information
OPKO’s senior management will provide a business update, discuss third quarter financial results and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing (833) 630-0584 (U.S.) or (412) 317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.
A telephone replay will be available until November 15, 2022 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 5757952. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, whether our products will launch in all the territories in which they have been approved for sale, the timing of such launches, the ability to get beneficial pricing approvals, whether RAYALDEE prescriptions will increase, our product development efforts and the expected benefits of our products, whether the relationship with our business partners will be successful, whether our business partners will be able to commercialize our products and successfully utilize our technologies, our ability to market and sell any of our products in development, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
—Tables to Follow—
OPKO Health, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions)
Unaudited
| As of | |||||||
| September 30, 2022 | December 31, 2021 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 180.8 | $ | 134.7 | |||
| Assets held for sale | 0.0 | 315.0 | |||||
| Other current assets | 233.2 | 373.3 | |||||
| Total current assets | 414.0 | 823.0 | |||||
| In-process research and development and goodwill | 768.5 | 1,110.8 | |||||
| Other assets | 1,042.3 | 465.9 | |||||
| Total Assets | $ | 2,224.8 | $ | 2,399.7 | |||
| Liabilities and Equity: | |||||||
| Accounts payable | $ | 49.8 | $ | 82.0 | |||
| Accrued expenses | 112.0 | 193.5 | |||||
| Current portion of convertible notes | 70.6 | 0.0 | |||||
| Liabilities associated with assets held for sale | 0.0 | 28.2 | |||||
| Other current liabilities | 34.8 | 26.3 | |||||
| Total current liabilities | 267.2 | 330.0 | |||||
| Long term portion of convertible notes | 141.8 | 187.9 | |||||
| Deferred tax liabilities | 135.1 | 148.5 | |||||
| Other long-term liabilities, principally contract liabilities, leases, contingent consideration and lines of credit | 51.6 | 48.2 | |||||
| Total Liabilities | 595.7 | 714.6 | |||||
| Equity | 1,629.1 | 1,685.1 | |||||
| Total Liabilities and Equity | $ | 2,224.8 | $ | 2,399.7 | |||
OPKO Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in millions, except share and per share data)
Unaudited
| For the three months ended September 30, | For the nine months ended September 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Revenues | |||||||||||||||
| Revenue from services | $ | 142.8 | $ | 340.1 | $ | 616.3 | $ | 1,244.3 | |||||||
| Revenue from products | 32.4 | 36.9 | 104.9 | 106.5 | |||||||||||
| Revenue from transfer of intellectual property and other | 4.5 | 8.8 | 97.7 | 22.6 | |||||||||||
| Total revenues | 179.7 | 385.8 | 818.9 | 1,373.4 | |||||||||||
| Costs and expenses | |||||||||||||||
| Cost of revenues | 148.4 | 244.0 | 586.7 | 900.4 | |||||||||||
| Selling, general and administrative | 79.7 | 105.1 | 298.7 | 330.6 | |||||||||||
| Research and development | 18.8 | 18.3 | 54.4 | 55.8 | |||||||||||
| Contingent consideration | (0.8 | ) | (0.5 | ) | (0.7 | ) | (1.6 | ) | |||||||
| Amortization of intangible assets | 21.4 | 12.6 | 66.2 | 37.8 | |||||||||||
| Gain on sale of assets | 0.0 | (31.5 | ) | (15.4 | ) | (31.5 | ) | ||||||||
| Total costs and expenses | 267.5 | 348.0 | 989.9 | 1,291.5 | |||||||||||
| Operating income (loss) | (87.8 | ) | 37.8 | (171.0 | ) | 81.9 | |||||||||
| Other expense, net | (38.6 | ) | (6.4 | ) | (118.3 | ) | (30.1 | ) | |||||||
| Income (loss) before income taxes and investment losses | (126.4 | ) | 31.4 | (289.3 | ) | 51.8 | |||||||||
| Income tax benefit (provision) | 40.3 | (2.7 | ) | 46.5 | (8.0 | ) | |||||||||
| Income (loss) before investment losses | (86.1 | ) | 28.7 | (242.8 | ) | 43.8 | |||||||||
| Loss from investments in investees | (0.0 | ) | (0.0 | ) | (0.4 | ) | (0.2 | ) | |||||||
| Net income (loss) | $ | (86.1 | ) | $ | 28.7 | $ | (243.2 | ) | $ | 43.6 | |||||
| Income (loss) per share, basic and diluted | $ | (0.11 | ) | $ | 0.04 | $ | (0.34 | ) | $ | 0.07 | |||||
| Weighted average common shares outstanding, basic and diluted | 750,396,263 | 651,843,074 | 708,121,980 | 646,710,240 | |||||||||||
FAQ
What were OPKO Health's Q3 2022 financial results?
How did OPKO's revenue in Q3 2022 compare to Q3 2021?
What caused the decline in OPKO's revenues in Q3 2022?
What is the outlook for OPKO's NGENLA product?
What impact did the ModeX acquisition have on OPKO's Q3 financials?
